$222 Million is the total value of Ghost Tree Capital, LLC's 74 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNKKQ | New | MALLINCKRODT PUB LTD CO | $7,673,000 | – | 120,000 | +100.0% | 3.45% | – |
| AMGN | New | AMGEN INC | $6,916,000 | – | 50,000 | +100.0% | 3.11% | – |
| GILD | New | GILEAD SCIENCES INC | $6,873,000 | – | 70,000 | +100.0% | 3.09% | – |
| CELG | New | CELGENE CORP | $6,490,000 | – | 60,000 | +100.0% | 2.92% | – |
| New | ALNYLAM PHARMACEUTICALS INCcall | $6,027,000 | – | 75,000 | +100.0% | 2.71% | – | |
| New | BRISTOL MYERS SQUIBB COcall | $5,920,000 | – | 100,000 | +100.0% | 2.66% | – | |
| EW | New | EDWARDS LIFESCIENCES CORP | $5,687,000 | – | 40,000 | +100.0% | 2.56% | – |
| CYH | New | COMMUNITY HEALTH SYS INC NEW | $5,132,000 | – | 120,000 | +100.0% | 2.31% | – |
| ZGNX | New | ZOGENIX INC | $4,995,000 | – | 370,000 | +100.0% | 2.25% | – |
| HTWR | New | HEARTWARE INTL INC | $4,708,000 | – | 90,000 | +100.0% | 2.12% | – |
| IART | New | INTEGRA LIFESCIENCES HOLDINGS CORP | $4,466,000 | – | 75,000 | +100.0% | 2.01% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $4,049,000 | – | 165,000 | +100.0% | 1.82% | – |
| HCA | New | HCA HOLDINGS INC | $3,868,000 | – | 50,000 | +100.0% | 1.74% | – |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $3,400,000 | – | 250,000 | +100.0% | 1.53% | – |
| PCRX | New | PACIRA PHARMACEUTICALS INC | $3,288,000 | – | 80,000 | +100.0% | 1.48% | – |
| SGYPQ | New | SYNERGY PHARMACEUTICALS INC | $3,180,000 | – | 600,000 | +100.0% | 1.43% | – |
| SPNC | New | SPECTRANETICS CORP | $2,948,000 | – | 250,000 | +100.0% | 1.33% | – |
| New | THERAPEUTICSMD INCcall | $2,930,000 | – | 500,000 | +100.0% | 1.32% | – | |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $2,906,000 | – | 200,000 | +100.0% | 1.31% | – |
| INCY | New | INCYTE CORP | $2,758,000 | – | 25,000 | +100.0% | 1.24% | – |
| ACOR | New | ACORDA THERAPEUTICS INC | $2,651,000 | – | 100,000 | +100.0% | 1.19% | – |
| New | HERON THERAPEUTICS INCcall | $2,440,000 | – | 100,000 | +100.0% | 1.10% | – | |
| RLYP | New | RELYPSA INC | $2,221,000 | – | 120,000 | +100.0% | 1.00% | – |
| ZFGN | New | ZAFGEN INC | $2,077,000 | – | 65,000 | +100.0% | 0.94% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS | $2,073,000 | – | 300,000 | +100.0% | 0.93% | – |
| New | NEURODERM LTD | $2,067,000 | – | 100,000 | +100.0% | 0.93% | – | |
| New | PTC THERAPEUTICS INCcall | $2,003,000 | – | 75,000 | +100.0% | 0.90% | – | |
| DSCI | New | DERMA SCIENCES INC | $1,413,000 | – | 300,000 | +100.0% | 0.64% | – |
| ACHC | New | ACADIA PHARMACEUTICALS | $1,323,000 | – | 40,000 | +100.0% | 0.60% | – |
| RGNX | New | REGENXBIO INC | $1,322,000 | – | 60,000 | +100.0% | 0.60% | – |
| CHMA | New | CHIASMA INC | $1,292,000 | – | 65,000 | +100.0% | 0.58% | – |
| CORI | New | CORIUM INTERNATIONAL INC | $1,169,000 | – | 125,000 | +100.0% | 0.53% | – |
| CPRX | New | CATALYST PHARM PARTNERS INC | $1,050,000 | – | 350,000 | +100.0% | 0.47% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $776,000 | – | 400,000 | +100.0% | 0.35% | – |
| New | BIODELIVERY SCIENCES INTL INcall | $590,000 | – | 106,200 | +100.0% | 0.27% | – | |
| AKTX | New | AKARI THERAPEUTICS PLC | $488,000 | – | 20,325 | +100.0% | 0.22% | – |
| FATE | New | FATE THERAPEUTICS INC | $476,000 | – | 89,231 | +100.0% | 0.21% | – |
| ONCE | New | SPARK THERAPEUTICS INC | $417,000 | – | 10,000 | +100.0% | 0.19% | – |
| ZSAN | New | ZOSANO PHARMA CORP | $396,000 | – | 100,000 | +100.0% | 0.18% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $321,000 | – | 10,000 | +100.0% | 0.14% | – |
| RPTP | New | RAPTOR PHARMACEUTICAL CORP | $303,000 | – | 50,000 | +100.0% | 0.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
| 13F-HR | 2021-11-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.